Rene Russo

CIK: 0001722066

Transaction Breakdown

Open Market Buys (P)1 (4.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (8.7%)

Derivative conversions

Awards (A)12 (52.2%)

Compensation grants

Other (G, F, J, C, D, …)8 (34.8%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

XLO

Xilio Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (23 total)

XLO
Xilio Therapeutics, Inc.
Jan 1, 2026
Exercise(M)
Direct
44.3K shares-
XLO
Xilio Therapeutics, Inc.
Dec 31, 2025
Award(A)
Stock Option (right to buy)
Direct
1.5M shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
700K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
2.1M shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
239.7K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
239.7K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
473.3K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
473.3K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
135.1K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
135.1K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
50K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
50K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
100K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
100K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
150K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
150K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
350K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
350K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
700K shares-
XLO
Xilio Therapeutics, Inc.
Jun 16, 2025
Purchase(P)
Direct
36.3K shares at avg. $0.68$25K
XLO
Xilio Therapeutics, Inc.
Apr 15, 2025
Award(A)
Stock Option (right to buy)
Direct
190K shares-
XLO
Xilio Therapeutics, Inc.
Jan 1, 2025
Exercise(M)
Direct
44.3K shares-
XLO
Xilio Therapeutics, Inc.
Jan 1, 2025
Award(A)
Stock Option (right to buy)
Direct
638K shares-

		Type	Shares	Price		Ownership
Jan 1, 2026	XLO Xilio Therapeutics, Inc.	Exercise(M)	44,250	-	$0	Direct
Dec 31, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	1,500,258	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	700,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	2,075,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	239,703	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	239,703	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	473,334	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	473,334	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	135,134	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	135,134	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	50,041	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	50,041	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	100,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	100,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	150,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	150,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	350,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	350,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	700,000	-	-	Direct
Jun 16, 2025	XLO Xilio Therapeutics, Inc.	Purchase(P)	36,289	$0.68	$24,680	Direct
Apr 15, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	190,000	-	-	Direct
Jan 1, 2025	XLO Xilio Therapeutics, Inc.	Exercise(M)	44,250	-	$0	Direct
Jan 1, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	638,000	-	-	Direct

1-23 of 23 transactions

About Russo Rene

Russo Rene (SEC CIK 0001722066) files insider reports with the SEC as PRESIDENT AND CEO of Xilio Therapeutics, Inc. (XLO).

Signal8 holds 6 ownership filings by Russo Rene, all Form 4s, filed between Jan 3, 2025 and Jan 5, 2026. Those filings report 23 transactions, from Jan 1, 2025 to Jan 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Russo Rene's filings is in WALTHAM, MA.

Recent filings by Russo Rene

Jan 1, 2026: Option exercise of XLO shares (Form 4, code M).
Dec 31, 2025: Grant or award of XLO derivative securities (Form 4, code A).
Nov 21, 2025: Disposition to issuer transaction of XLO derivative securities (Form 4, code D).
Nov 21, 2025: Grant or award of XLO derivative securities (Form 4, code A).
Nov 21, 2025: Disposition to issuer transaction of XLO derivative securities (Form 4, code D).

Other insiders filing for Xilio Therapeutics, Inc. (XLO)

Houvras Yariv, CHIEF MEDICAL OFFICER
Bello Akintunde Olatokumbo, Director
Shannon James Samuel, Director
Curran Daniel J., Director
Xu Yuan, Director
ROSS ROBERT W., Director

How to read Form 4 transaction codes